10.1038/s41591-024-02934-7 - Pemigatinib in previously treated sol...

This document has been corrected

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

10.1038/s41591-024-02934-7

Published Online: 2024-05-06

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: Aidan Gilmartin•Antoine Italiano•Hiroo Imai•Iben Spanggaard•Jesús García-Donas•Jordi Rodón•Lipika Goyal•Makoto Ueno•Maria Luisa Veronese•Michael Schaffer•Muhammad Furqan•Natalia Oliveira•Silvia Damian•Tomoya Yokota•Xin Li

This document has been corrected

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

10.1038/s41591-024-02934-7

Published Online: 2024-05-06

Journal: Nature Medicine

NOW

2024-05-24•Correction

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

10.1038/s41591-024-03072-w

* information provided by CrossRef

2024-05-24•Correction

10.1038/s41591-024-03072-w

* information provided by CrossRef

2024-05-06•Published

2024-05-24•Correction

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

10.1038/s41591-024-03072-w

* information provided by CrossRef

This document has been corrected

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

10.1038/s41591-024-02934-7

Published Online: 2024-05-06

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC